

Express Mail Label No.: EV 330 994 768 US
Date: October 17, 2003

Attorney Docket No. VPI/00-102 CON DIV3 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Michael R. Hale, et al.
DIVISIONAL APPLICATION OF: 10/335,793 EXAMINER: Robert Ramsuer
FILING DATE: Herewith ART UNIT: 1626
FOR: PYRAZOLE COMPOUNDS USEFUL AS INHIBITORS OF ERK

October 17, 2003
Cambridge, Massachusetts 02139-4242

MS PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the


APPLICANTS: **Hale, et al.**
U.S.S.N.: **Not Yet Assigned**

cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-102 CON DIV3 US.

Respectfully submitted,



Andrea L. C. Robidoux, Reg. No. 47,902
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139-4242
Tel: (617) 444-6731
Fax: (617) 444-6483

Express Mail Label No.: EV 330 994 768 US
Date: October 17, 2003

Attorney Docket No. VPI/00-102 CON DIV3 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Michael R. Hale, et al.
DIVISIONAL APPLICATION OF: 10/335,793 EXAMINER: Robert Ramsuer
FILING DATE: Herewith ART UNIT: 1626
FOR: PYRAZOLE COMPOUNDS USEFUL AS INHIBITORS OF ERK

October 17, 2003
Cambridge, Massachusetts 02139-4242

MS PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the

APPLICANTS: Hale, et al.
U.S.S.N.: Not Yet Assigned

cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-102 CON DIV3 US.

Respectfully submitted,



Andrea L. C. Robidoux, Reg. No. 47,902
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
 130 Waverly Street
 Cambridge, Massachusetts 02139-4242
 Tel: (617) 444-6731
 Fax: (617) 444-6483

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned
	Filing Date	Herewith
	First Named Inventor	Jeremy Green
	Group Art Unit	1626
	Examiner Name	Robert W. Ramsuer
	Attorney Docket Number	VPI/00-102 CON DIV3 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,932,576	08/03/99	Anantanarayan, et al.	514	235.5	
	A2*	5,922,741	07/13/99	Davis, et al.	514	341	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1*		FR 2 707 295	Rhone Poulenc	13-Jan-1995		X
	B2*		WO 98/52941	Searle	26-Nov-1998		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Ambiter company catalog, dated August 23, 1999, discloses the compound "1H-pyrrole-2-carboxamide,N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)". Copy not available to applicants.
	C2*	Jones, et al., Pyrrole studies. Part XXIII. 1,3-Dipolar addition reactions with vinylpyrroles", Heterocycles, 14(2):185-188 (1980) (see in particular page 186, Table I).
	C3*	Zhestkov, et al., Synthesis and biological activity of pyrrole-substituted pyrazole-5-ones", Khim.-Farm. Zh., 16(6):47-52 (1982) (see in particular page 48, Table I).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned
	Filing Date	Herewith
	First Named Inventor	Jeremy Green
	Group Art Unit	1626
	Examiner Name	Robert W. Ramsuer
	Attorney Docket Number	VPI/00-102 CON DIV3 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,932,576	08/03/99	Anantanarayan, et al.	514	235.5	
	A2*	5,922,741	07/13/99	Davis, et al.	514	341	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1*		FR 2 707 295	Rhone Poulenc	13-Jan-1995		X
	B2*		WO 98/52941	Searle	26-Nov-1998		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Ambiter company catalog, dated August 23, 1999, discloses the compound "1H-pyrrole-2-carboxamide,N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)". Copy not available to applicants.
	C2*	Jones, et al., Pyrrole studies. Part XXIII. 1,3-Dipolar addition reactions with vinylpyrroles", Heterocycles, 14(2):185-188 (1980) (see in particular page 186, Table I).
	C3*	Zhestkov, et al., Synthesis and biological activity of pyrrole-substituted pyrazole-5-ones", Khim.-Farm. Zh., 16(6):47-52 (1982) (see in particular page 48, Table I).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.